#ntrk

Is the "Diamond Target" (NTRK Fusion) the key to precision oncology?

A breakthrough in Medical Tourism China: Next-Generation NTRK inhibitors are showing remarkable results, including a 100% intracranial objective response rate for brain metastases.

At MedBridgeNZ, we understand that navigating global healthcare can be complex. As a premier medical concierge provider, we don't provide medical treatment ourselves, but we specialize in connecting international patients with top-tier specialists and clinical trials in China.

Read our latest article to learn about these advanced therapies and how they are changing the landscape of cancer care.

👇 Next-Gen NTRK Inhibitors China: Unlocking the "Diamond Target" for Cancer Treatment

Researchers find NTRK fusions more common than expected in pediatric tumors

Credit: CC0 Public Domain In a large study of pediatric cancer patients, researchers from Children’s Hospital of Philadelphia (CHOP) have analyzed the frequency, fusion partners, and clinical outcome of neurotrophic tyrosine receptor kinase (NTRK) fusions, which are clinical biomarkers that identify patients suitable for treatment with FDA-approved TRK inhibitors. The researchers found that NTRK…